SuperworthNeurogene market cap NGNE
Share price times shares outstanding: what the whole company sells for, since 2014.
- Today, Oct 23, 2026
- $471.3M
- Highest close in our data
- $886.3M
- Nov 2024
Neurogene is worth $471.3M at the close on Oct 23, 2026, at $23.55 a share.
That is up 10% over the last year and up 52% over five years.
Its highest close in our data was $886.3M in Nov 2024.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $471.3M | $266.9M | $773M | +52% |
| 2025 | $310M | $131.2M | $489M | −9% |
| 2024 | $341.2M | $53.9M | $886.3M | +649% |
| 2023 | $45.5M | $21.7M | $45.5M | +110% |
| 2022 | $21.7M | $17.9M | $174M | −89% |
| 2021 | $204.5M | $204.5M | $588.6M | −65% |
| 2020 | $590.7M | $260.6M | $651.9M | +27% |
| 2019 | $466.9M | $54.1M | $466.9M | +858% |
| 2018 | $48.7M | $48.7M | $388.3M | −82% |
| 2017 | $275.9M | $248M | $456.5M | −29% |
| 2016 | $386.7M | $111.7M | $389.1M | +80% |
| 2015 | $214.8M | $16.2M | $237.4M | +196% |
| 2014 | $72.5M | $60M | $109.2M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Neurogene's size, closest first, today.
| Company | Market cap |
|---|---|
| NGNENeurogene | $471.3M |
| ARVNArvinas | $477.3M |
| PBYIPuma Biotechnology | $568.9M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $582.6M |
| CRMDCorMedix | $611.9M |
| COLLCollegium Pharmaceutical | $747.5M |
| ABUSArbutus Biopharma | $831M |
| NATRNatures Sunshine Products | $213.8M |
| AMPHAmphastar Pharmaceuticals | $1.1B |
| OMEROmeros | $1.2B |
| Peer median | $597.2M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Neurogene
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.